Verve Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERV research report →
Range $13 – $30
Price Chart
About the company
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver.
- CEO
- Sekar Kathiresan
- IPO
- 2021
- Employees
- 274
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on VERV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $994.04M
- P/E
- -4.72
- PEG
- -0.14
- P/S
- 30.74
- P/B
- 1.91
- EV/EBITDA
- -4.02
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -707.23%
- Net Margin
- -614.59%
- ROE
- -36.36%
- ROIC
- -37.19%
Latest fiscal year · YoY change
- Revenue
- $32.33M+175.0%
- Gross Profit
- $32.33M+175.0%
- Op Income
- $-228,660,000
- Net Income
- $-198,709,000+0.7%
- EPS
- $-2.36+24.4%
- OCF Growth
- -5.4%
- FCF Growth
- -1.6%
- 52W High
- $11.40
- 52W Low
- $2.87
- 50D MA
- $8.21
- 200D MA
- $6.45
- Beta
- 2.24
- RSI (14)
- 76
- Avg Volume
- 5.72M
No earnings-call transcripts are available for VERV yet.
- Free Float
- 73.2%
- Shares Outstanding
- 89.31M
- Float Shares
- 65.37M
of shares held by institutions
195 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 6.62M | ▲ 1.25M |
| Nuveen Asset Management, LLC | 1.32M | ▼ 355.95K |
| Sandy Spring Bank | 2.60K | 0 |
| Lindbrook Capital, LLC | 929 | 0 |
| Clarivest Asset Management LLC | 584 | 0 |
Held by 3 ETFs
Biggest fund positions in VERV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 25, 25 | GV 2017 GP, L.L.C. | other | 1,800,000 |
| Jul 25, 25 | MacLean Michael F | sell | 136,139 |
| Jul 25, 25 | MacLean Michael F | sell | 42,200 |
| Jul 25, 25 | Yeshwant Krishna | sell | 136,139 |
| Jul 25, 25 | Yeshwant Krishna | sell | 42,200 |
| Jul 25, 25 | Yeshwant Krishna | other | 1,800,000 |
| Jul 25, 25 | Dorval Allison | sell | 75,000 |
| Jul 25, 25 | Dorval Allison | other | 13,280 |
| Jul 25, 25 | Dorval Allison | sell | 1,875 |
| Jul 25, 25 | Dorval Allison | sell | 180,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VERV coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VERV?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Three Biotechs That Are Top Takeover Targets
247wallst.com · May 18
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
prnewswire.com · Jul 25
Lilly and Verve announce expiration of Verve tender offer
prnewswire.com · Jul 24
3 Bullish Biotech Stocks With Explosive Growth Trends
marketbeat.com · Jul 21
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
fool.com · Jun 20
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)
globenewswire.com · Jun 20
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
businesswire.com · Jun 18
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
zacks.com · Jun 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
